Key result
Hispanic heart failure patients show similar ACEI/ARB compliance to peers, but only ~21% reach target doses.
Why the study?
Are Hispanic patients with systolic heart failure as compliant with evidence-based medications as white and black patients in a disease management program?
Cross-Sectional (n=561)
No
Are Hispanic patients with systolic heart failure as compliant with evidence-based medications as white and black patients in a disease management program?
Hispanic patients with systolic heart failure in a disease management program demonstrate similar compliance with evidence-based medications compared to white and black patients, though target dose achievement remains low across all groups.
Supports comparable adherence in Hispanics within similar HFDMPs; leaves open generalizability and outcome impact.
The Hispanic population is the fastest growing minority in the United States, yet there is a paucity of data regarding patient follow-up in heart failure disease management programs (HFDMPs) and evidence-based medication adherence. The purpose of this study is to measure the compliance of evidence-based medication use, specifically measuring angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and beta-blockers (BBs) in the Hispanic population, and compare these data to the white and black population. The authors conducted a cross-sectional study of 561 patients enrolled in an HFDMP at Jackson Medical Hospital in Miami, Florida. At the first visit, 82% of Hispanic, 75% of white, and 79% of black patients were taking ACEIs/ARBs, but only 21% of Hispanic, 35% of white, and 32% of black patients were taking target doses. Hispanic patients are as compliant with ACEI/ARB and BB regimens as are the white and black populations in HFDMPs in a setting of similar socioeconomic features.
No takes yet. Share an insight, caveat, or question.
Hebert et al. (2010) conducted a cross-sectional in Systolic Heart Failure (n=561). Hispanic ethnicity vs. White and black populations was evaluated on Compliance with evidence-based medication use (ACEIs/ARBs) at the first visit. Hispanic patients with systolic heart failure showed similar compliance to ACEI/ARB therapy (82%) compared to white (75%) and black (79%) patients, though only 21% were at target doses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: